http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#Head http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#assertion http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#provenance http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#pubinfo http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#assertion http://purl.obolibrary.org/obo/DOID_5844 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5844 http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01079 http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association http://www.w3.org/2000/01/rdf-schema#label "ZELNORM is contraindicated in patients with: A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina [see Warnings and Precautions (5.1) A history of ischemic colitis or other forms of intestinal ischemia [see Warnings and Precautions (5.2) Severe renal impairment (eGFR< 15 mL/min/1.73 m 2 [see Use in Specific Populations (8.6) Moderate and severe hepatic impairment (Child-Pugh B or C) [see Use in Specific Populations (8.7) A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions [see Adverse Reactions (6.2) Hypersensitivity to tegaserod [see Adverse Reactions (6.2) ZELNORM is contraindicated in patients with: A history of myocardial infarction, stroke, transient ischemic attack, or angina. ( 4 5.1 A history of ischemic colitis or other forms of intestinal ischemia. ( 4 5.2 Severe renal impairment (eGFR< 15 mL/min/1.73 m 2 4 8.6 Moderate or severe hepatic impairment (Child-Pugh B or C). ( 4 8.7 A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions. ( 4 Hypersensitivity to tegaserod. ( 4" http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB01079 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#provenance http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#pubinfo http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig http://purl.org/nanopub/x/hasSignature HMpAN/ZLAiirJ0dlGD2UuaPZ7LKEBwrf2JA4ZsjRPcg2IJ0rov5ynpWH9odQraW2JKDIExFrpyJqG7XB53q9ysnb6ceOxqO1r1BhZH20ivER7b12CBzWRThwvtaYTJxibEkRo5mG6J7G2XX+oPaTclLx92lBGH8NkaFT7RTPUhI= http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://purl.org/dc/terms/created 2021-08-23T19:01:06.583+02:00 http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA0UFXrlBNciWJp7kKelPDD3ZvmW6fpjsaBKB0m_YNuDM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY